Pipeline
Our lead program is azelaprag, a potential first-in-class oral therapeutic for obesity, if approved, followed by several earlier-stage metabolic programs
Our lead program is azelaprag, a potential first-in-class oral therapeutic for obesity, if approved, followed by several earlier-stage metabolic programs
Program
Mechanism of Action
Route of administration
Indication
Status
Azelaprag
(BGE-105)
(BGE-105)
APJ agonist
Oral
Obesity (tirzepatide co-administration)
Obesity (semaglutide co-administration)
Type 2 diabetes
Ph 2
![]()
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Ph 2
![]()
Planning in process
Planning in process
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Ph 2
![]()
Planning in process
Planning in process
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
NLRP3
NLRP3 inhibitor
Oral
Metabolic disease & neuroinflammation
IND-enabling
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Discovery
Undisclosed metabolic
-
-
Disc.
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Program
Azelaprag
(BGE-105)
Azelaprag
(BGE-105)
Azelaprag
(BGE-105)
Mechanism of Action
APJ agonist
Route of administration
Oral
Indication
Obesity (tirzepatide co-administration)
Status
Ph 2
![]()
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Mechanism of Action
APJ agonist
Route of administration
Oral
Indication
Obesity (semaglutide co-administration)
Status
Ph 2
![]()
Planning in process
Planning in process
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Mechanism of Action
APJ agonist
Route of administration
Oral
Indication
Type 2 diabetes
Status
Ph 2
![]()
Planning in process
Planning in process
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Program
NLRP3
-
Mechanism of Action
NLRP3 inhibitor
Route of administration
Oral
Indication
Metabolic disease & neuroinflammation
Status
IND-enabling
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Program
Discovery
-
Mechanism of Action
Undisclosed metabolic
Route of administration
-
Indication
-
Status
Disc.
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
